PWS DESK Independent handbook · 中文 ES

This site is not the association. US crisis calls: pwsausa.org · 941-312-0400. We do not answer that phone.

Retro educational comic drawing of a brass balance scale holding a tablet bottle and nasal spray bottle beside a steel padlock and clipboard
HYPERPHAGIA THERAPEUTICS · UPDATED 2026-11-16

DCCR withdrawal vs carbetocin in PWS: 2026 trial data

Two peer-reviewed Phase 3 publications in 2026 separated Prader-Willi syndrome hyperphagia treatments with hard clinical endpoints: a 16-week randomized withdrawal trial of diazoxide choline extended-release (DCCR) and the 12-week COMPASS PWS trial of intranasal carbetocin. Here is what each trial proved, what failed, and why physical food security remains mandatory.

DIRECT ANSWER

Continued diazoxide choline extended-release (DCCR) prevented hyperphagia rebound in a 2026 randomized withdrawal trial, keeping HQ-CT scores 5.0 points lower than placebo (P=0.0022). Conversely, intranasal carbetocin failed to separate from placebo in the 175-person Phase 3 COMPASS PWS study (P=0.79), leaving food locks essential alongside therapy.

2026 PHASE 3 HYPERPHAGIA OUTCOMES (HQ-CT & WEIGHT) Panel 1 plots HQ-CT score change from baseline across COMPASS PWS carbetocin vs placebo (-4.8 vs -5.1, P=0.79) and the DCCR 16-week withdrawal trial (+2.6 continued vs +7.6 placebo rebound, P=0.0022). Panel 2 maps age-stratified nutritional phases against treatment and safety windows. 1. HQ-CT SCORE CHANGE (LOWER = BETTER) COMPASS Carbetocin (n=85) -4.8 (SE 0.8) COMPASS Placebo (n=90) -5.1 (SE 0.8) | P=0.79 Continued DCCR (n=38) +2.6 (SE 1.12) Placebo Withdrawal (n=39) +7.6 (SE 1.09) | P=0.0022 -6 -3 0 +3 +6 +9 2. TREATMENT, WEIGHT & AGE WINDOWS 16-wk Weight Diff: -1.6 kg (-3.1, -0.1) BMI z-score Diff: -0.09 (-0.17, -0.01) COMPASS TEAEs: Headache 7.2%, Pyrexia 6.0% AGE-STRATIFIED LOCK & THERAPY TIMELINE 2.1y: Ph2a weight rise -> start food locks 4+ y: DCCR FDA label floor (Vykat XR) 8+ y: Ph3 hyperphagia -> HQ-CT tracking 18+ y: Adult locks + ongoing GI vigilance
2026 PEER-REVIEWED EVIDENCE

Two 2026 Phase 3 readouts split the hyperphagia pipeline

Between May and July 2026, two randomized, double-blind, placebo-controlled studies published in peer-reviewed journals gave clinicians and caregivers the clearest contrast yet across Prader-Willi syndrome hyperphagia pharmacology. For decades, families trying to evaluate candidate medicines had to navigate small pilot studies, open-label extensions, and anecdotal caregiver impressions. Because Prader-Willi syndrome involves profound hypothalamic satiety impairment driven by loss of paternally expressed 15q11-q13 genes such as SNURF-SNRPN and MAGEL2 (see our molecular sources), caregivers urgently needed blinded randomized data showing whether targeted drugs meaningfully move validated behavioral endpoints.

In May 2026, the Journal of Clinical Endocrinology and Metabolism published the 16-week randomized withdrawal study of diazoxide choline extended-release (DCCR) tablets in children and adults aged 4 years and older (Journal of Clinical Endocrinology and Metabolism, 2026). All 77 enrolled participants had previously completed an initial 13-week randomized trial followed by 2.5 to 4.5 years of open-label DCCR treatment. Investigators then randomized them 1:1 in a double-blind withdrawal period: 38 continued once-daily DCCR while 39 were switched silently to matching placebo. Over 16 weeks, participants withdrawn to placebo experienced a sharp rebound in food-seeking behaviors, with a least-squares (LS) mean change of +7.6 points (SE 1.09) on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) compared with +2.6 points (SE 1.12) in those continuing DCCR (P = 0.0022). Weight and body composition shifted in the same direction: the placebo withdrawal group gained significantly more weight, yielding an LS mean weight difference of -1.6 kg (95% CI -3.1 to -0.1) and a BMI z-score difference of -0.09 (95% CI -0.17 to -0.01) favoring continued DCCR, with no serious adverse events reported in the DCCR arm during the withdrawal period.

Two months later, in July 2026, Clinical Therapeutics published the full peer-reviewed results of COMPASS PWS (ClinicalTrials NCT06173531; Clinical Therapeutics, 2026), the confirmatory 12-week Phase 3 trial of intranasal carbetocin (3.2 mg three times daily). Designed to confirm nominal improvements seen earlier in CARE-PWS (ClinicalTrials NCT03649477), COMPASS PWS randomized 175 participants 1:1 to carbetocin (n=85) or placebo (n=90). At week 12, the LS mean change from baseline in HQ-CT total score was -4.8 (SE 0.8) with carbetocin versus -5.1 (SE 0.8) with placebo, a non-significant treatment difference of +0.3 points (95% CI -1.8 to 2.4; P = 0.79). There was zero separation on secondary endpoints, including Clinical Global Impression of Severity (CGI-S), Clinical Global Impression of Change (CGI-C), the proportion achieving at least an 8-point HQ-CT response, or the PWS Anxiousness and Distress Behaviors Questionnaire. The most frequent treatment-emergent adverse events in carbetocin recipients were headache (7.2%, n=6) and pyrexia (6.0%, n=5). Intranasal carbetocin did not demonstrate efficacy over placebo.

How the HQ-CT score works and why placebo responses complicate trials

Understanding why COMPASS PWS failed while DCCR succeeded in a withdrawal design requires understanding how hyperphagia is measured. Unlike blood glucose or serum IGF-1 levels, there is no simple blood test for hypothalamic hunger. Clinical trials rely on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT), a 9-item caregiver-reported scale scoring food-seeking behaviors, sneaking, emotional distress around denied meals, and time spent talking about food on a 0-to-36 point scale.

Because HQ-CT relies on caregiver observation during structured clinic visits, entering a clinical trial often improves family routines temporarily: caregivers keep closer daily logs, reinforce mealtime schedules, and tighten kitchen supervision. In COMPASS PWS, that structured trial effect pushed the placebo group's HQ-CT score down by 5.1 points in just 12 weeks, matching the -4.8-point change in the active nasal spray arm. In contrast, the DCCR withdrawal study tested participants who had already been stabilized on open-label DCCR for 2.5 to 4.5 years. Because families did not know who was switched to placebo, removing active KATP channel modulation unmasked an immediate biological rebound (+7.6 points vs +2.6 points) and measurable weight gain (+1.6 kg difference). For a broader view of active and discontinued programs, see our full 2025 to 2026 drugs and trials table.

What diazoxide choline does biologically and where locks stay mandatory

Why does diazoxide choline alter hyperphagia while other mechanisms struggle? A December 2025 mechanistic analysis in Genes (Genes, 2025) examined the molecular network around KCNJ11 and the Kir6.2 subunit of ATP-sensitive potassium (KATP) channels activated by diazoxide choline. By opening KATP channels in pancreatic beta cells and hypothalamic neurons, diazoxide choline hyperpolarizes cell membranes, suppresses excess insulin secretion (hyperinsulinemia), and modulates downstream pathways governing energy storage, fatty acid synthesis, and hypothalamic appetite signaling.

However, both clinical outcomes and regulatory surveillance prove that KATP modulation is a partial physiological brake, not a cure. First, even in the DCCR withdrawal study, patients who remained on DCCR still had measurable hyperphagia scores (+2.6 change over 16 weeks) and required strict environmental control. Second, because diazoxide choline inhibits insulin release and alters potassium-mediated membrane excitability across tissues, families must monitor closely for fluid retention, peripheral edema, elevated fasting glucose or hemoglobin A1c, and hypertrichosis, as tracked in our Vykat safety signal review. Third, as detailed in a December 2025 review in the International Journal of Molecular Sciences on neuropeptides and the autonomic nervous system in PWS (International Journal of Molecular Sciences, 2025), hypothalamic and MAGEL2-linked dysfunction impairs sympathetic, parasympathetic, and enteric nervous system signaling independently of subjective hunger. Delayed gastric emptying, blunted visceral pain perception, and abnormal thermoregulation remain present even when food-seeking decreases, meaning an unguarded binge can still trigger acute gastric dilation or necrosis (see our emergency red-flag protocol).

How families should align drug monitoring with nutritional phases and autonomic risks

For caregivers coordinating pediatric or adult endocrinology visits, the practical takeaway from 2025 to 2026 trials is how pharmacotherapy fits inside Miller's age-stratified nutritional phases rather than replacing them. Around median age 2.08 years (Nutritional Phase 2a), weight rises before overt food-seeking begins, making early food storage locks the primary intervention well before the FDA-approved age floor of 4 years for Vykat XR (FDA orphan listing, 2025). Once overt hyperphagia emerges around median age 8 (Phase 3, covered on our hyperphagia guide), families considering DCCR should combine baseline and quarterly fasting glucose/HbA1c checks, peripheral edema checks, and IEP no-sharing food plans. Before any planned procedure or sedation, remember that DCCR and PWS autonomic features require strict perioperative planning (see surgery and anaesthesia), and during adolescence, sex steroid replacement must be tracked separately to preserve bone mineral density (see hypogonadism).

Program / Agent Mechanism & Trial Design 2025 to 2026 Primary Endpoint Outcome Safety & Caregiver Action
DCCR / Vykat XR
(Journal of Clinical Endocrinology and Metabolism, 2026)
KATP channel agonist (Kir6.2); 16-wk randomized double-blind withdrawal (N=77; age ≥4 yr) Continued DCCR prevented rebound: HQ-CT +2.6 vs +7.6 placebo (P=0.0022); weight diff -1.6 kg FDA approved (Mar 2025, age ≥4); monitor glucose/HbA1c & edema (Vykat safety); keep food locks
Carbetocin (COMPASS PWS)
(Clinical Therapeutics, 2026)
Intranasal oxytocin analog 3.2 mg TID; 12-wk Phase 3 RCT (N=175; ClinicalTrials NCT06173531) Missed primary endpoint: HQ-CT -4.8 vs -5.1 placebo (diff +0.3, P=0.79); no secondary gain Headache 7.2%, pyrexia 6.0%; development discontinued; do not pursue compounded sprays
Oral ARD-101
(ClinicalTrials NCT05153434)
Bitter taste receptor (TAS2R) gut-hormone agonist; Phase 2 exploratory study (N=19) Early-phase exploratory trial completed; awaiting larger blinded Phase 3 confirmation Investigational only; verify active registry status on drugs and trials
Environmental & Autonomic Care
(International Journal of Molecular Sciences, 2025)
Physical kitchen/trash locks + school IEP rules + GI/autonomic vigilance across all ages Prevents unguarded binges, gastric necrosis, and severe obesity regardless of drug response Mandatory from ~2 yr (food security) through adulthood; vomiting + bloating = ED

Common questions

What did the 2026 DCCR withdrawal trial prove about stopping diazoxide choline?

In a 16-week randomized double-blind withdrawal study published in JCEM in 2026 (N=77), participants switched from long-term diazoxide choline extended-release (DCCR) to placebo experienced a +7.6-point rebound on the HQ-CT hyperphagia score compared with +2.6 points on continued DCCR (P=0.0022), alongside a 1.6 kg greater weight gain on placebo.

Why did carbetocin nasal spray fail in the COMPASS PWS Phase 3 trial?

In the 12-week randomized COMPASS PWS trial (NCT06173531, N=175) published in Clinical Therapeutics in 2026, carbetocin 3.2 mg three times daily changed HQ-CT scores by -4.8 points versus -5.1 points with placebo (difference +0.3, P=0.79). Neither hyperphagia nor anxiousness endpoints separated from placebo.

Can families stop locking food storage once a child starts Vykat XR?

No. Even with continued DCCR therapy in clinical trials, hyperphagia scores are reduced rather than eliminated, and 2025 to 2026 autonomic and gastric reviews confirm that delayed gastric emptying, blunted pain perception, and binge-triggered gastric necrosis persist. Food locks remain mandatory.

Sources: Journal of Clinical Endocrinology and Metabolism, 2026 · Clinical Therapeutics, 2026 · Genes, 2025 · International Journal of Molecular Sciences, 2025 · ClinicalTrials NCT06173531 · ClinicalTrials NCT05153434 · FDA orphan listing, 2025